CA2304000A1 - Antagoniste du recepteur de la vitronectine - Google Patents
Antagoniste du recepteur de la vitronectine Download PDFInfo
- Publication number
- CA2304000A1 CA2304000A1 CA002304000A CA2304000A CA2304000A1 CA 2304000 A1 CA2304000 A1 CA 2304000A1 CA 002304000 A CA002304000 A CA 002304000A CA 2304000 A CA2304000 A CA 2304000A CA 2304000 A1 CA2304000 A1 CA 2304000A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- cells
- compound according
- medicament
- manufacture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
L'invention porte sur un composé de formule (I) qui est un antagoniste du récepteur de la vitronectine et qui est utile dans le traitement de l'ostéoporose, ou sur un sel de celui-ci, acceptable en pharmacie.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5986797P | 1997-09-24 | 1997-09-24 | |
US60/059,867 | 1997-09-24 | ||
PCT/US1998/019987 WO1999015178A1 (fr) | 1997-09-24 | 1998-09-24 | Antagoniste du recepteur de la vitronectine |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2304000A1 true CA2304000A1 (fr) | 1999-04-01 |
Family
ID=22025805
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002304000A Abandoned CA2304000A1 (fr) | 1997-09-24 | 1998-09-24 | Antagoniste du recepteur de la vitronectine |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1023073A1 (fr) |
JP (1) | JP2002500162A (fr) |
KR (1) | KR20010024249A (fr) |
CN (1) | CN1271284A (fr) |
AU (1) | AU9578798A (fr) |
BR (1) | BR9813214A (fr) |
CA (1) | CA2304000A1 (fr) |
HU (1) | HUP0003931A2 (fr) |
IL (1) | IL135188A0 (fr) |
NO (1) | NO20001515D0 (fr) |
PL (1) | PL339414A1 (fr) |
TR (1) | TR200000786T2 (fr) |
WO (1) | WO1999015178A1 (fr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1150965A4 (fr) | 1999-02-03 | 2002-05-15 | Merck & Co Inc | Derives de la benzazepine utilises comme antagonistes du recepteur alpha-v de l'integrine |
US6514964B1 (en) | 1999-09-27 | 2003-02-04 | Amgen Inc. | Fused cycloheptane and fused azacycloheptane compounds and their methods of use |
EP1381384B1 (fr) | 2001-04-24 | 2011-05-25 | Merck Patent GmbH | POLYTHERAPIE A BASE D'AGENTS ANTIANGIOGENIQUES ET DE FACTEUR DE NECROSE TUMORALE TNFalpha |
WO2003059251A2 (fr) | 2001-10-22 | 2003-07-24 | The Scripps Research Institute | Composes de ciblage d'anticorps |
EP1628949A4 (fr) | 2003-04-04 | 2008-07-02 | Smithkline Beecham Corp | Procede et produits intermediaires pour preparer des benzazepines |
CA2554644C (fr) | 2004-02-02 | 2015-06-16 | Pioneer Hi-Bred International, Inc. | Facteur de transcription odp2 (ovule development protein 2) du domaine ap2 et procedes pour l'utiliser |
UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
EP2335733B1 (fr) | 2006-01-18 | 2014-08-06 | Merck Patent GmbH | Thérapie spécifique utilisant des ligands d'intégrine pour traiter le cancer |
CN101588812A (zh) | 2007-01-18 | 2009-11-25 | 默克专利有限公司 | 使用整联蛋白配体治疗癌的特异疗法和药物 |
CA2705916C (fr) | 2007-11-16 | 2016-01-05 | Ube Industries, Ltd. | Compose de benzazepinone |
WO2009111679A2 (fr) * | 2008-03-06 | 2009-09-11 | Smithkline Beecham Corporation | Procédé |
WO2010093706A2 (fr) | 2009-02-10 | 2010-08-19 | The Scripps Research Institute | Vaccination programmée chimiquement |
US20120095215A1 (en) | 2009-03-30 | 2012-04-19 | Ube Industries, Ltd. | Medical composition for treatment or prophylaxis of eye diseases |
WO2010136168A2 (fr) | 2009-05-25 | 2010-12-02 | Merck Patent Gmbh | Administration continue de ligands d'intégrines pour le traitement du cancer |
AU2010339404B2 (en) | 2009-12-30 | 2016-01-28 | Pioneer Hi-Bred International, Inc. | Methods and compositions for the introduction and regulated expression of genes in plants |
AU2010339481B2 (en) | 2009-12-30 | 2016-02-04 | Pioneer Hi-Bred International, Inc. | Methods and compositions for targeted polynucleotide modification |
EP3148587B1 (fr) | 2014-05-30 | 2021-02-24 | Pfizer Inc | Dérivés carbonitriles en tant que modulateurs sélectifs du récepteur des androgènes |
WO2023275715A1 (fr) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Métabolites de modulateurs sélectifs du récepteur des androgènes |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA60311C2 (uk) * | 1996-10-02 | 2003-10-15 | Смітклайн Бічам Корпорейшн | Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція |
-
1998
- 1998-09-24 CA CA002304000A patent/CA2304000A1/fr not_active Abandoned
- 1998-09-24 BR BR9813214-8A patent/BR9813214A/pt not_active Application Discontinuation
- 1998-09-24 AU AU95787/98A patent/AU9578798A/en not_active Abandoned
- 1998-09-24 CN CN98809494A patent/CN1271284A/zh active Pending
- 1998-09-24 HU HU0003931A patent/HUP0003931A2/hu unknown
- 1998-09-24 WO PCT/US1998/019987 patent/WO1999015178A1/fr not_active Application Discontinuation
- 1998-09-24 TR TR2000/00786T patent/TR200000786T2/xx unknown
- 1998-09-24 KR KR1020007003093A patent/KR20010024249A/ko not_active Application Discontinuation
- 1998-09-24 EP EP98949471A patent/EP1023073A1/fr active Pending
- 1998-09-24 PL PL98339414A patent/PL339414A1/xx unknown
- 1998-09-24 JP JP2000512547A patent/JP2002500162A/ja not_active Withdrawn
- 1998-09-24 IL IL13518898A patent/IL135188A0/xx unknown
-
2000
- 2000-03-23 NO NO20001515A patent/NO20001515D0/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
HUP0003931A2 (hu) | 2001-10-28 |
JP2002500162A (ja) | 2002-01-08 |
WO1999015178A1 (fr) | 1999-04-01 |
PL339414A1 (en) | 2000-12-18 |
CN1271284A (zh) | 2000-10-25 |
KR20010024249A (ko) | 2001-03-26 |
EP1023073A1 (fr) | 2000-08-02 |
NO20001515L (no) | 2000-03-23 |
NO20001515D0 (no) | 2000-03-23 |
AU9578798A (en) | 1999-04-12 |
IL135188A0 (en) | 2001-05-20 |
TR200000786T2 (tr) | 2000-08-21 |
BR9813214A (pt) | 2000-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU733417B2 (en) | Vitronectin receptor antagonists | |
CA2304000A1 (fr) | Antagoniste du recepteur de la vitronectine | |
WO1999015170A1 (fr) | Antagoniste du recepteur de vitronectine | |
AU738433B2 (en) | Vitronectin receptor antagonists | |
US6495560B1 (en) | Vitronectin receptor antagonist | |
US20020019387A1 (en) | Vitronectin receptor antagonist | |
EP1102587A2 (fr) | Antagonistes du recepteur de la proteine s | |
US20020128257A1 (en) | Vitronectin receptor antagonist | |
US6576643B2 (en) | Vitronectin receptor antagonists | |
MXPA00002895A (en) | Vitronectin receptor antagonist | |
CZ20001061A3 (cs) | Antagonista receptoru pro vitronektin | |
MXPA00002896A (en) | Vitronectin receptor antagonist | |
CZ20001060A3 (cs) | Antagonista receptoru vitronektinu | |
CZ2000979A3 (cs) | Antagonista vitronektinového receptoru |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |